Related Experiment Video
Updated: Mar 25, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.2K
Chimeric antigen receptor T cell treatment in hematologic malignancies
Hakan Goker1, Umit Yavuz Malkan1, Haluk Demiroglu1
1School of Medicine, Department of Internal Medicine, Division of Hematology, Hacettepe University, Ankara, Turkey.
Summary
Chimeric antigen receptor (CAR) T-cell therapy shows promise for treating blood cancers like leukemia and lymphoma. This review covers CAR-T cell efficacy and potential adverse effects in hematological malignancies.
Area of Science:
- Immunotherapy
- Oncology
- Genetics
Background:
- Hematological malignancies represent a significant area of unmet medical need.
- Adoptive immunotherapy using genetically engineered T cells is an emerging treatment strategy.
- Chimeric antigen receptor (CAR) T-cell therapy offers targeted cancer recognition.
Purpose of the Study:
- To review the current understanding of CAR T-cell therapy in hematological malignancies.
- To highlight the efficacy of CAR T-cell treatments.
- To discuss the adverse effects associated with CAR T-cell therapy.
Main Methods:
- Literature review of reported and ongoing studies on CAR T-cell therapy.
- Analysis of CAR T-cell application in leukemia, myeloma, and lymphomas.
- Synthesis of current knowledge on CAR T-cell efficacy and safety.
Main Results:
- CAR T-cell therapy demonstrates encouraging results in treating various blood cancers.
- Selective recognition of tumor-associated antigens by CAR T cells is a key mechanism.
- Ongoing research continues to expand the application of this therapy.
Conclusions:
- CAR T-cell therapy is a promising modality for hematological malignancies.
- Understanding efficacy and adverse effects is crucial for clinical application.
- Further research is warranted to optimize CAR T-cell treatments.
